Siddarth Arumugam et al devised a rapid microfluidic test that could detect Lyme disease with similar performance as the standard 2-tiered (STT) algorithm recommended for the laboratory diagnosis of the disease, in a much shorter time of 15 minutes. The researchers used human serum characterized as acute and convalescent early Lyme disease, Lyme arthritis, and post-treatment Lyme disease syndrome, as well as the necessary controls (n=241 samples) to screen for diagnostic Borrelia burgdorferi protein biomarkers to improve sensitivity of the microfluidic assay (mChip-Ld). They then tested the top three biomarkers -antigen VlsE and a synthetic 33-mer peptide (PepVF) to capture sensitivity in all disease stages, and OspC for early Lyme disease. The team observed that mChip-LD could pick up signs of Lyme disease infection in early-stage samples with a specificity of 80-85%, compared to a 48.5% and 75% sensitivity of the STT method. The results encourage for development of single, multiplexed diagnostic test that can help identify Lyme disease stage.
Source: Journal of Clinical Microbiology October 9, 2019 DOI https://doi.org/10.1128/JCM.01142-19\